[Diseases caused by human papilloma viruses]
- PMID: 21560109
- DOI: 10.1055/s-0031-1275845
[Diseases caused by human papilloma viruses]
Abstract
Human papilloma viruses are responsible for a large number of benign and malignant lesions of the skin. HPV 6 and 11 cause up to 90 % of condylomata. Almost each cervical cancer is associated with HPV. HPV 16 und 18 induce up to 70 % of cervical neoplasias. The vaccination against HPV is internationally implemented and should be applied to young girls aged 12 to 17 according to STIKO criteria. The vaccination may reduce the rate of cervical cancer by 70 % and the rate of cervical intraepithelial neoplasia by 50 %. Many studies demonstrated the efficacy and safetyness of both vaccines. Gardasil (®) offers protection against HPV 6, 11, 16 and 18, Cervarix (®) against HPV 16 and 18. Protection against condylomata is offered by the quadrivalent vaccine in 90 %. The bivalent vaccine has demonstrated type-specific protection against the five most frequent cancer inducing types (16, 18, 31, 33, 45). The production of VLPs is an innovative technology. A comparison of both vaccines, Cervarix (®) and Gardasil (®), showed a higher immunogenicity for Cervarix (®). In Germany the immunization rates are still low comparing to other countries. As a method for secondary prevention of cervical cancer the PAP smear is still an effective method.
© Georg Thieme Verlag KG Stuttgart · New York.
Similar articles
-
Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.J Natl Cancer Inst. 2010 Mar 3;102(5):325-39. doi: 10.1093/jnci/djp534. Epub 2010 Feb 5. J Natl Cancer Inst. 2010. PMID: 20139221 Clinical Trial.
-
Cost-consequences evaluation between bivalent and quadrivalent HPV vaccines in Italy: the potential impact of different cross-protection profiles.Gynecol Oncol. 2011 Jun 1;121(3):514-21. doi: 10.1016/j.ygyno.2011.01.029. Epub 2011 Feb 19. Gynecol Oncol. 2011. PMID: 21334734
-
Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years old.Clin Vaccine Immunol. 2012 Feb;19(2):261-7. doi: 10.1128/CVI.05208-11. Epub 2011 Dec 7. Clin Vaccine Immunol. 2012. PMID: 22155768 Free PMC article. Clinical Trial.
-
Currently approved prophylactic HPV vaccines.Expert Rev Vaccines. 2009 Dec;8(12):1663-79. doi: 10.1586/erv.09.123. Expert Rev Vaccines. 2009. PMID: 19943762 Review.
-
A review of clinical trials of human papillomavirus prophylactic vaccines.Vaccine. 2012 Nov 20;30 Suppl 5(0 5):F123-38. doi: 10.1016/j.vaccine.2012.04.108. Vaccine. 2012. PMID: 23199956 Free PMC article. Review.
Cited by
-
The eye in sexually transmitted infections: a review of the ocular complications of venereal diseases.Int Ophthalmol. 2011 Dec;31(6):539-50. doi: 10.1007/s10792-011-9501-5. Epub 2012 Jan 4. Int Ophthalmol. 2011. PMID: 22215417 Review.
-
Coincidence of HPV11-Positive Urethral Condyloma Acuminatum and HPV-Negative Multiple Bladder Papillomas in a Female.Case Rep Med. 2012;2012:602819. doi: 10.1155/2012/602819. Epub 2012 Mar 4. Case Rep Med. 2012. PMID: 22474458 Free PMC article.